Verona Pharma plc (VRNA)
NASDAQ: VRNA · IEX Real-Time Price · USD
15.47
+0.16 (1.05%)
At close: Apr 26, 2024, 4:00 PM
15.74
+0.27 (1.75%)
After-hours: Apr 26, 2024, 4:11 PM EDT
Verona Pharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Verona Pharma stock have an average target of 33.6, with a low estimate of 32 and a high estimate of 36. The average target predicts an increase of 117.19% from the current stock price of 15.47.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verona Pharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $31 → $36 | Buy | Maintains | $31 → $36 | +132.71% | Apr 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +106.85% | Mar 4, 2024 |
| Wedbush | Wedbush | Buy Reiterates $33 | Buy | Reiterates | $33 | +113.32% | Mar 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +106.85% | Jan 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +106.85% | Dec 29, 2023 |
Financial Forecast
Revenue This Year
32.11M
Revenue Next Year
152.37M
from 32.11M
Increased by 374.48%
EPS This Year
-1.21
from -0.72
EPS Next Year
-0.47
from -1.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 48.5M | 220.5M | 419.4M | 706.8M | 941.1M |
| Avg | 32.1M | 152.4M | 313.7M | 553.3M | 780.7M |
| Low | 7.8M | 98.0M | 228.0M | 404.3M | 555.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 586.6% | 175.2% | 125.3% | 70.1% |
| Avg | - | 374.5% | 105.9% | 76.4% | 41.1% |
| Low | - | 205.2% | 49.7% | 28.9% | 0.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.80 | 0.67 | 1.98 | 3.72 | 4.39 |
| Avg | -1.21 | -0.47 | 1.17 | 2.11 | 2.74 |
| Low | -1.42 | -1.40 | 0.51 | 0.38 | 0.55 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 218.7% | 107.5% |
| Avg | - | - | - | 81.3% | 29.4% |
| Low | - | - | - | -67.2% | -74.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.